This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (16)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Thrombolysis  • Drug Therapy, Other  • Alert me on articles by topic

Arch Intern Med. 1999;159:429-433.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

IT WOULD BE HARD to find anyone who disagrees that all health care practitioners should be concerned with the efficacy, safety, and cost of treatments provided to their patients. Most would also agree that the first 2 considerations should usually outweigh the third. However, today's climate in health care often seems to be focused increasingly on cost as the primary driver of care. As the economics become increasingly visible to the public and payers, the producers and consumers of health care often find themselves on opposing sides of positions related to fundings. Therefore, it is ever important that information used to make decisions related to the financing of care be unbiased and as easy as possible to understand. This ideal does not always occur. One area where passion and promotion rather than evidence are increasingly influencing decisions relates to the substitution of Food and Drug Administration (FDA)–approved generic equivalents for . . . [Full Text of this Article]

BANAHAN AND KOLASSA'S STUDY AND ITS IMPACT


PROBLEMS WITH GENERIC SWITCHING

ISSUES SURROUNDING SUBSTITUTION

COMMENT

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997-2000
Haas et al.
ANN INTERN MED 2005;142:891-897.
ABSTRACT | FULL TEXT